display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 451 ...
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 451 ...

Study type: